![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 1
Zeitschriftenartikel
Hoster, Eva 
ORCID: https://orcid.org/0000-0002-0749-1389; Delfau-Larue, Marie-Hélène ORCID: https://orcid.org/0000-0002-8010-2343; Macintyre, Elizabeth; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Stilgenbauer, Stephan; Vehling-Kaiser, Ursula; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Tilly, Hervé ORCID: https://orcid.org/0000-0001-7022-5246; Wirths, Stefan ORCID: https://orcid.org/0000-0003-2494-9862; Feugier, Pierre; Hübel, Kai; Schmidt, Christian; Ribrag, Vincent; Kluin-Nelemans, Johanna C. ORCID: https://orcid.org/0000-0003-2617-9427; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340
(2023):
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma. Results From the European Mantle Cell Lymphoma Elderly Trial.
In: Journal of Clinical Oncology, Bd. 42, Nr. 5: S. 538-549
ORCID: https://orcid.org/0000-0002-0749-1389; Delfau-Larue, Marie-Hélène ORCID: https://orcid.org/0000-0002-8010-2343; Macintyre, Elizabeth; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Stilgenbauer, Stephan; Vehling-Kaiser, Ursula; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Tilly, Hervé ORCID: https://orcid.org/0000-0001-7022-5246; Wirths, Stefan ORCID: https://orcid.org/0000-0003-2494-9862; Feugier, Pierre; Hübel, Kai; Schmidt, Christian; Ribrag, Vincent; Kluin-Nelemans, Johanna C. ORCID: https://orcid.org/0000-0003-2617-9427; Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249 und Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340
(2023):
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma. Results From the European Mantle Cell Lymphoma Elderly Trial.
In: Journal of Clinical Oncology, Bd. 42, Nr. 5: S. 538-549